Subscriber Content Preview | Request a free trialSearch  


Investment in reverse mergers doubled in second quarter

Young biotech companies took advantage of the transaction structure to go public. Continue reading

These five boards could be the worst

A look at some egregious pay practices, over-the-top takeover defenses and generally poor governance. There may be some groups that are even more awful, but we haven't found them. Continue reading

Shire agrees to $55B AbbVie takeover offer

The $55 billion transaction will boost morale among dealmakers after Pfizer's failed run at AstraZeneca. Continue reading

Fed health care pay affects PE exit

Vestar Capital-backed 21st Century already delayed its intial public offering, but acquirers may come calling in a rapidly consolidating sector. Continue reading

U.K. seeks new powers to shape takeovers

Business Secretary Vince Cable aims to develop a "fallback" weapon to intervene in takeovers on national interest grounds when a bidder refuses to negotiate. Continue reading

Omega Pharma founder confirms he's studying options

The OTC drugs maker is said to have hired Morgan Stanley to conduct a review. Continue reading

SEC issues tough guidance for proxy advisory firms

Agency restrictions could have impact on activist investor campaigns. Continue reading

After six mighty months, the next six look just as strong

Private equity firms won't take the summer off, and that could make for big transactions. It won't be a surprise if LBO shops go out and top the first half's eye-popping M&A figures. Continue reading

Shire rejects $46B AbbVie offer

The proposal followed two other pitches from AbbVie, which wants to move its tax domicile to the U.K. Continue reading

Valeant readies hostile exchange offer for Allergan

Tender offer is one of many strategies Valeant is launching in its $54 billion hostile takeover attempt. Continue reading

Medtronic to pay $43B for Ireland's Covidien

The Minneapolis buyer pledges to splurge on U.S. R&D in an apparent attempt to preempt an outcry about plans to redomicile in Ireland for tax purposes. Continue reading

Gabelli on Gabelli

Life's too short, as far as this long-term activist is concerned, to alter his value investing approach. "We're basically old-fashioned, green-eye shade investors." Continue reading

Meet the journalists

Pamela Taulbee

Senior Writer: Healthcare

Jim Cramer's 2013 M&A predictions

The Founder of and host of Mad Money makes his predictio ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

The Deal’s senior journalists host the industry's leading M&A forecasting event, an invitation-only gathering of influential members of the deal community discussing the outlook for dealmaking in the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!